Results 81 to 90 of about 1,231,953 (350)
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng +4 more
wiley +1 more source
Yuanyuan Li,1,* Qiaolin Yu,1,* Rong Yao,2 Xiaoyi Yang,2 Bin Wan,3 Xia Zhao,3 Yinping Hu,1 Yan Zhou,2 Li Dai,4 Xiaoli Liu,5 Enchun Xie,6 Fang Huang,7 Fanghui Xie,2 Zhouli Guo5 1The First Department of Tuberculosis, the Public Health ...
Li Y +13 more
doaj
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali +14 more
wiley +1 more source
Goal of study: to define species of non-tuberculosis mycobacteria, isolated from the respiratory tract of the patients from various Russian regions using DNA strips for identification of non-tuberculous mycobacteria.Materials and methods.
T. G. Smirnovа +5 more
doaj +1 more source
Primary thyroid gland tuberculosis: a conundrum in a child [PDF]
Sonam Sharma, Rachit Sharma
openalex +1 more source
Type I interferons in tuberculosis: Foe and occasionally friend
Type I interferons have been implicated in the pathogenesis of tuberculosis. Herein, Moreira-Teixeira et al. discuss mechanistic and contextual factors that determine the role of type I interferons during Mycobacterium tuberculosis infection, from human ...
Lúcia Moreira-Teixeira +3 more
semanticscholar +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
In 2015, more than 10% of tuberculosis (TB)-related deaths were attributable to M. tuberculosis with multiple drug-resistance (MDR-TB) and extensively drug-resistance (XDR-TB) (WHO 2016).
V. V. Eremeev +4 more
doaj +1 more source

